Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP

Pancreatic cancer is chemo-resistant and metastasizes early with an overall five-year survival of ∼8.2%. First-in-class imipridone ONC201 is a small molecule in clinical trials with anti-cancer activity. ONC212, a fluorinated-ONC201 analogue, shows preclinical efficacy in melanoma and hepatocellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Lev, Avital, Lulla, Amriti R., Wagner, Jessica, Ralff, Marie D., Kiehl, Joshua B., Zhou, Yan, Benes, Cyril H., Prabhu, Varun V., Oster, Wolfgang, Astsaturov, Igor, Dicker, David T., El-Deiry, Wafik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669847/
https://www.ncbi.nlm.nih.gov/pubmed/29137221
http://dx.doi.org/10.18632/oncotarget.20819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669847/
https://www.ncbi.nlm.nih.gov/pubmed/29137221
http://dx.doi.org/10.18632/oncotarget.20819

Ejemplares similares